Advances in pharmacotherapy for tobacco dependence
- PMID:15155135
- DOI: 10.1517/eoed.9.1.39.32951
Advances in pharmacotherapy for tobacco dependence
Abstract
The discovery that bupropion is an effective treatment for tobacco dependence has triggered a rapid increase in development of potential new non-nicotine pharmacotherapies, including bromocriptine, glucose, GTS-21, reboxetine, rimonabant, selegeline and varenicline. Successful new products will need to have excellent side-effect profiles in addition to proven efficacy. New faster delivery nicotine replacement products have the promise of addressing a broader list of indications, including treatment of nicotine withdrawal during temporary abstinence and long-term nicotine maintenance. Nicotine vaccines will need to demonstrate efficacy and also improve certain consumer acceptability characteristics (e.g., frequency of injections required) before they can become widely used and successful therapies. The best hope of improved treatment comes from combining existing and new pharmacotherapies with effective behavioural therapy.
Similar articles
- Pharmacotherapy for tobacco dependence.Fant RV, Buchhalter AR, Buchman AC, Henningfield JE.Fant RV, et al.Handb Exp Pharmacol. 2009;(192):487-510. doi: 10.1007/978-3-540-69248-5_17.Handb Exp Pharmacol. 2009.PMID:19184660Review.
- Bupropion for the treatment of nicotine withdrawal and craving.Mooney ME, Sofuoglu M.Mooney ME, et al.Expert Rev Neurother. 2006 Jul;6(7):965-81. doi: 10.1586/14737175.6.7.965.Expert Rev Neurother. 2006.PMID:16831112Review.
- Smoking cessation pharmacotherapy.Frishman WH.Frishman WH.Ther Adv Cardiovasc Dis. 2009 Aug;3(4):287-308. doi: 10.1177/1753944709335754. Epub 2009 Jun 2.Ther Adv Cardiovasc Dis. 2009.PMID:19491139Review.
- Developments in pharmacotherapy for tobacco dependence: past, present and future.Foulds J, Steinberg MB, Williams JM, Ziedonis DM.Foulds J, et al.Drug Alcohol Rev. 2006 Jan;25(1):59-71. doi: 10.1080/09595230500459529.Drug Alcohol Rev. 2006.PMID:16492578Review.
- Pharmacotherapy of tobacco dependence.Talwar A, Jain M, Vijayan VK.Talwar A, et al.Med Clin North Am. 2004 Nov;88(6):1517-34. doi: 10.1016/j.mcna.2004.07.011.Med Clin North Am. 2004.PMID:15464111Review.
Cited by
- Expanding treatment of tobacco dependence.Harris DS, Anthenelli RM.Harris DS, et al.Curr Psychiatry Rep. 2005 Oct;7(5):344-51. doi: 10.1007/s11920-005-0034-3.Curr Psychiatry Rep. 2005.PMID:16216152Review.
- Exploring the role of a nicotine quantity-frequency use criterion in the classification of nicotine dependence and the stability of a nicotine dependence continuum over time.McBride O, Strong DR, Kahler CW.McBride O, et al.Nicotine Tob Res. 2010 Mar;12(3):207-16. doi: 10.1093/ntr/ntp196. Epub 2010 Jan 15.Nicotine Tob Res. 2010.PMID:20081041Free PMC article.
- How do we safely get people to stop smoking?Lam DC, Minna JD.Lam DC, et al.Cancer Prev Res (Phila). 2011 Nov;4(11):1724-7. doi: 10.1158/1940-6207.CAPR-11-0449.Cancer Prev Res (Phila). 2011.PMID:22052339Free PMC article.
- Tobacco smoking and the ADRA2A C-1291G polymorphism.Prestes AP, Marques FZ, Hutz MH, Roman T, Bau CH.Prestes AP, et al.J Neural Transm (Vienna). 2007;114(11):1503-6. doi: 10.1007/s00702-007-0769-6. Epub 2007 Jul 6.J Neural Transm (Vienna). 2007.PMID:17612790
- Inflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics.Jan M, Meng S, Chen NC, Mai J, Wang H, Yang XF.Jan M, et al.J Biomed Biotechnol. 2010;2010:459798. doi: 10.1155/2010/459798. Epub 2010 Apr 15.J Biomed Biotechnol. 2010.PMID:20414374Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical